RESUMEN
2' and 7 Polyol carbonates of paclitaxel were synthesized and screened as potential paclitaxel prodrugs. Paclitaxel is released from 7-(2",3"-dihydroxypropylcarbonato) paclitaxel (Protaxel) at rates inversely proportional to pH, by an intramolecular cyclization. Compared to paclitaxel, maximum tolerated i.v. or i.p. doses (MTD) of Protaxel are about 2.5- to 3-fold higher; its efficacy is substantially higher in human cancer line xenografts in athymic mice, especially in prostate PC-3, breast MDA-MB 468 and ovary OVCAR-1.
Asunto(s)
Antineoplásicos/síntesis química , Antineoplásicos/farmacología , Paclitaxel/análogos & derivados , Paclitaxel/síntesis química , Paclitaxel/farmacología , Profármacos/síntesis química , Profármacos/farmacología , Taxoides , Animales , Antineoplásicos/toxicidad , Neoplasias de la Mama/tratamiento farmacológico , División Celular/efectos de los fármacos , Estabilidad de Medicamentos , Tolerancia a Medicamentos , Femenino , Semivida , Humanos , Concentración de Iones de Hidrógeno , Masculino , Dosis Máxima Tolerada , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Neoplasias Ováricas/tratamiento farmacológico , Paclitaxel/toxicidad , Profármacos/toxicidad , Neoplasias de la Próstata/tratamiento farmacológico , Ratas , Ratas Sprague-Dawley , Solubilidad , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
A series of dinucleoside 5-polyphosphates UpnU (n = 2-7) was synthesized. Their relative potencies as agonists at the G-protein-coupled receptors P2Y1, P2Y2, P2Y4, and P2Y6 were determined by intracellular calcium measurements using fluorescent imaging techniques. The correlation of phosphate chain length to activities at these receptors is discussed.